Neutralizing Granulocyte/Macrophage Colony-Stimulating Factor Inhibits Cigarette Smoke-induced Lung Inflammation

Funding Acknowledgements

Supported by the National Health and Medical Research Council of Australia.R.V. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.P.J.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. S.I. is a full-time employee of AstraZeneca R&D, Lund, Sweden. A.L. received

,001-$5,000 from GlaxoSmithKline Sweden in advisory board fees, ,001-$5,000 from AstraZeneca Sweden in lecture fees, and has private ownership of a non-provisional U.S. patent application (unrelated area). J.A.H. received ,001-$5,000 from MorphoSys AG in consultancy fees, more than 00,001 from MorphoSys AG in royalties (licensing fees and milestone payments made), and holds a patent from MorphoSys. J.A.H's employer, the University of Melbourne, has licensed patented technology. G.P.A. received ,001-$5,000 from MorphoSys AG in consultancy fees and more than 00,001 from MorphoSys AG in royalties. Licensing fees and Milestone payments made to the University of Melbourne by MorphoSys AG in relation to GM-CSF technology. G.P.A.'s employer, the University of Melbourne, has licensed patented technology relating to therapeutically targeting GM-CSF to MorphoSys AG, Germany. Licensing fees and milestone payments made to the University of Melbourne by MorphoSys AG in relation to GM-CSF technology were in the 00,001 or more dollar range.